Qyuns Therapeutics Co., Ltd.

SEHK:2509 Stock Report

Market Cap: HK$2.0b

Qyuns Therapeutics Valuation

Is 2509 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2509 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2509's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2509's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2509?

Key metric: As 2509 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2509. This is calculated by dividing 2509's market cap by their current revenue.
What is 2509's PS Ratio?
PS Ratio30.9x
SalesCN¥59.67m
Market CapCN¥1.85b

Price to Sales Ratio vs Peers

How does 2509's PS Ratio compare to its peers?

The above table shows the PS ratio for 2509 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.4x
1061 Essex Bio-Technology
0.9xn/aHK$1.5b
1875 TOT BIOPHARM International
1.4x20.5%HK$1.5b
2315 Biocytogen Pharmaceuticals (Beijing)
2.8x22.4%HK$2.4b
2181 Mabpharm
8.5xn/aHK$1.4b
2509 Qyuns Therapeutics
30.9xn/aHK$2.0b

Price-To-Sales vs Peers: 2509 is expensive based on its Price-To-Sales Ratio (30.9x) compared to the peer average (3.4x).

Price to Sales Ratio vs Industry

How does 2509's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
6826 Shanghai Haohai Biological Technology
2.2x11.8%US$1.88b
1530 3SBio
1.5x9.3%US$1.72b
2696 Shanghai Henlius Biotech
1.8x10.4%US$1.42b
775 CK Life Sciences Int'l. (Holdings)
0.8xn/aUS$568.03m
2509 30.9xIndustry Avg. 12.0xNo. of Companies14PS01632486480+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 2509 is expensive based on its Price-To-Sales Ratio (30.9x) compared to the Hong Kong Biotechs industry average (12x).

Price to Sales Ratio vs Fair Ratio

What is 2509's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2509 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 2509's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

3SBio

HK$13.4b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.69

7D

-2.4%

1Y

-23.1%

China Shineway Pharmaceutical Group

HK$6.2b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.27

7D

-0.7%

1Y

n/a

United Laboratories International Holdings

HK$18.5b

An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.

3933

HK$10.16

7D

0.4%

1Y

28.4%